Cardiol Therapeutics (TSX:CRDL) Additional Paid-In Capital : C$17.21 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Additional Paid-In Capital?

Cardiol Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 (C$18.52 Mil) to Dec. 2023 (C$18.79 Mil) but then stayed the same from Dec. 2023 (C$18.79 Mil) to Mar. 2024 (C$17.21 Mil).

Cardiol Therapeutics's annual additional paid-in capital increased from Dec. 2021 (C$12.66 Mil) to Dec. 2022 (C$15.59 Mil) and increased from Dec. 2022 (C$15.59 Mil) to Dec. 2023 (C$18.79 Mil).

Cardiol Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Cardiol Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Additional Paid-In Capital Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

4.77

8.77

12.66

15.59

18.79

Cardiol Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															15.94	16.57	18.52	18.79	17.21

Cardiol Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cardiol Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre

Senior Officer